Pfizer Corporation

Wyeth

University of Minnesota

Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Annaliesa Sybil Anderson

Kathrin Ute Jansen

Mark Edward Ruppen

Justin Keith Moran

Robert G K Donald

Michael James Flint

Maninder K Sidhu

Narender Kumar Kalyan

Lakshmi Khandke

Susan Kay Hoiseth

Gary Warren Zlotnick

Thomas Richard Jones

John Erwin Farley

John Lance Perez

Shannon Lea Harris

Leah Diane Fletcher

Ingrid Lea Scully

Avvari Krishna Prasad

Paul A Liberator

Jason Arnold Lotvin

Ellen Murphy

Bruce Arthur Green

Amardeep Singh Bhupender Bhalla

Viliam Pavliak

Jasdeep Singh Nanra

Johannes Frederik Beeslaar

Judith Absalon

Jianxin Gu

Jin-Hwan Kim

David Cooper

Rasappa Gounder Arumugham

Bounthon Loun

Weiqiang Sun

Lynn Marie Phelan

Ingrid Lea Dodge

Isis Kanevsky

Jose Miguel Aste-Amezaga

Suddham Singh

Miguel Angel Garcia

Steven Morris Baker

Laurent Oliver Chorro

Rosalind Pan

Yekaterina Timofeyeva

Lei Hu

Emily Mara Braunstein

Dorys Garcia-Hand

Eduardo Arturo Rojas

Leena Shriram Bagle

Rajesh Kumar Kainthan

Wei Chen

A Krishna Prasad

Loren D Schultz

Cindy Xudong Yang

Michael Hagen

Srinivas Kodali

Nishith Merchant

Ling Chu

Scott Ellis Lomberk

Stephen Bruce Olmsted

Karen Kiyoko Takane

Stephen John Freese

Tracy Dee Scott

Liesel A Bernfield

Tessie Brown McNeely

Paul Patrick Cleary

William L McClements

Rosemarie Kelly

Donna Lorraine Montgomery

Eugene Joseph Vidunas

James C Cook, Iii

Robert George Konrad Donald

Mark E Ruppen

Deborah Ann Dilts

Jason Douglas Maguire

Cuiwen Tan

Jacqueline Marie Lypowy

Robert G Donald

P Patrick Cleary

Terri L Mininni

Robert GK Donald

Patrick P Cleary

William L Mcclements

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

Neisseria meningitidis compositions and methods thereof

This invention relates to compositions that include a polypeptide derived fromor a fragment thereof; and modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof, and methods of use thereof.

compositions and methods thereof

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Immunogenic compositions and uses thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturingand in producingtoxins.

Compositions and methods relating to a mutanttoxin

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and anon-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response againstserogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 &#x3bc;g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 &#x3bc;g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to a non-lipidated and non-pyruvylatedserogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide fromserogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

composition and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutanttoxin and methods thereof

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B, and methods related thereto.

Non-lipidated variants ofORF2086 antigens

Growing community of inventors

Upper Saddle River, NJ, United States of America

Annaliesa Sybil Anderson